Trial reportGut and liver2022
Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant
Trial report in Gut and liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- A Nationwide Trend Analysis ofGut and liver · 2026Article
- Practical Efficacy of a 1-Week Metronidazole-Based Triple Regimen Plus Bismuth Versus a 2-Week Bismuth-Based Quadruple Regimen for Helicobacter pylori Infection With Clarithromycin-Resistance-Associated Genetic Mutations.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Antimicrobial susceptibility of clinicalMicrobiology spectrum · 2024Article
- [Comprehensive Analysis of Factors Associated WithThe Korean journal of helicobacter and upper gastrointestinal research · 2024Article
- Article
- Independent Risk Factors Predicting Eradication Failure of Hybrid Therapy for the First-Line Treatment ofMicroorganisms · 2023Article
- Types of 23S Ribosomal RNA Point Mutations AffectingThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility ofGut and liver · 2023Article
- Efficacy of 7-day Tailored Therapy forThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- [Bismuth, An Indispensable Component ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- [Evidence-based Therapy: A Rational Approach toThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Bismuth-Based Quadruple Therapy for Clarithromycin-ResistantGut and liver · 2022Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Clarithromycin resistance is a main factor for treatment failure in the context of Methods: This was a multicenter, randomized, controlled trial. A total of 782 patients with Results: The overall genotypic clarithromycin resistance rate was 25.7% according to the sequencing method. The eradication rate of 14-day bismuth-based quadruple therapy was not significantly different in the intention-to-treat analysis (80.4% vs 69.7%, p=0.079), but was significantly higher than that of 14-day metronidazole-intensified triple therapy in the per-protocol analysis (95.1% vs 76.4%, p=0.001). There were no significant differences in the incidence of side effects. In addition, the 14-day bismuth-based quadruple therapy was more cost-effective than the 14-day metronidazole-intensified triple therapy. Conclusions: Fourteen-day bismuth-based quadruple therapy showed comparable efficacy with 14-day metronidazole-intensified triple therapy, and it was more cost-effective in the context of clarithromycin-resistant
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.